Sullivan Timothy Eugene's Form 4 filing
Apellis Pharmaceuticals, Inc. (APLS) · filed Jan 21, 2025
- Accession no.
- 0001127602-25-001627
- Filed
- Jan 21, 2025
- Trade date
- Jan 17-21, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $51.8K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sullivan Timothy EugeneCIK 0001707000 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 17, 2025 | Common Stock | SSaleDisposed | −1,730 | $29.96 | −$51,830.8 | 86,370 | Direct | |
| Jan 21, 2025 | Common Stock | AGrant or awardAcquired | +45,929 | $0.00 | $0 | 132,299 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.